<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991859</url>
  </required_header>
  <id_info>
    <org_study_id>203162</org_study_id>
    <nct_id>NCT02991859</nct_id>
  </id_info>
  <brief_title>Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects</brief_title>
  <official_title>An Escalating Dose, Randomized, Placebo-controlled, Incomplete-block, 2-period Cross-over Study to Assess the Dose Response for Topical Efficacy Via Airway Responsiveness to Adenosine-5'-Monophosphate (AMP) Challenge and the Dose Response for Systemic Activity Via 24 Hour (h) Plasma Cortisol Suppression and Thereby the Relative Therapeutic Index for Fluticasone Furoate (FF), Fluticasone Propionate (FP) and Budesonide (BUD) in Asthmatic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study,
      aiming to investigate whether higher potency of different inhaled corticosteroid confers an
      improvement in the topical efficacy to systemic activity ratio in asthmatic subjects. It will
      compare the dose response for topical efficacy via airway responsiveness (to
      adenosine-5'-monophosphate [AMP] challenge), and the dose response for systemic activity via
      24 hour plasma cortisol suppression, and thereby compare the relative therapeutic index, for
      the following inhaled corticosteroids: fluticasone furoate (FF), fluticasone propionate (FP)
      and budesonide (BUD).

      There will be a screening visit 7-28 days before the first dose of study treatment, and a
      minimum 4-day run-in period before the first dose of study treatment. Subjects will be
      randomized to one of 12 treatment sequences, and will have two treatment periods, each
      comprising 5 consecutive 7-day phases of escalating doses of either FF, FP, BUD or placebo.
      There will be a 25- to 42-day washout period between treatment periods. The study duration
      for each subject will be approximately 22 weeks including the follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Anticipated">December 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative concentration (PC) of AMP causing a 20% reduction in forced expiratory volume in 1 second (FEV1) (AMP PC20)</measure>
    <time_frame>At Day 7 (12 hours post dose) of each escalation phase in both treatment periods</time_frame>
    <description>AMP is used as stimulus to cause bronchoconstriction. The AMP challenges will be done 12 hour post-evening dose on Day 7 after each 7-day dose escalation phase of each treatment period (Treatment periods 1 and 2). Subjects will inhale doubling increments of AMP (0.04, 0.08, 0.16, 0.32, 0.63, 1.25, 2.5, 5.0, 10.0, 20.0, 40.0, 80.0, 160.0 and 320.0 milligram [mg]/milliliter [mL]) until a &gt;=20% fall in FEV1 from the post-diluent value is achieved or the highest permitted dose of AMP (320 mg/mL) is achieved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour weighted mean plasma cortisol suppression</measure>
    <time_frame>Day 6 to Day 7 of each escalation phase in both treatment periods</time_frame>
    <description>Blood samples will be collected for a 24 hour period from pre-dose evening dose on Day 6 to pre-dose evening dose on Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose at which 20% cortisol suppression is reached ([ED20] cortisol suppression)</measure>
    <time_frame>Day 6 to Day 7 of each escalation phase in both treatment periods</time_frame>
    <description>Blood samples will be collected for a 24 hour period from pre-dose evening dose on Day 6 to predose evening dose on Day 7. Maximum effect (Emax) model will be used to obtain the ED20 0-24 hour weighted mean cortisol suppression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose at which 80% of the maximum AMP PC20 is reached ([ED80] for AMP PC20)</measure>
    <time_frame>Day 6 to Day 7 of each escalation phase in both treatment periods</time_frame>
    <description>The AMP challenges will be done 12 hour post-evening dose on Day 7 after each 7 day dose escalation phase of each treatment period. Maximum effect (Emax) model will be used to obtain the ED80 for AMP PC20.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with any adverse event (AE) and any serious adverse event (SAE) as a measure of safety and tolerability</measure>
    <time_frame>Approximately 22 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow rate (PEFR) as a measure of safety and tolerability</measure>
    <time_frame>On Days 1, 8, 15, 22, and 29 in both treatment periods</time_frame>
    <description>PEFR is a subject's maximum speed of expiration and will be measured using a peak flow meter. Subjects need to record the highest PEFR measurement in paper diary (before each dose) of three maneuvers attempted twice daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure (BP) as a measure of safety</measure>
    <time_frame>Days 1 (pre-dose) and 36 in both treatment periods</time_frame>
    <description>Vital signs will be measured after subjects have been rested in supine position for at least 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate as a measure of safety</measure>
    <time_frame>Days 1 (pre-dose) and 36 in both treatment periods</time_frame>
    <description>Vital signs will be measured after subjects have been rested in supine position for at least 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature as a measure of safety</measure>
    <time_frame>Days 1 (pre-dose) and 36 in both treatment periods</time_frame>
    <description>Vital signs will be measured after subjects have been rested in supine position for at least 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate as a measure of safety</measure>
    <time_frame>Days 1 (pre-dose) and 36 in both treatment periods</time_frame>
    <description>Vital signs will be measured after subjects have been rested in supine position for at least 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations as a measure of safety</measure>
    <time_frame>At Screening and Follow-up (at approximately Week 22)</time_frame>
    <description>A complete physical examination will include, at a minimum, assessment of the cardiovascular, respiratory, gastrointestinal, skin, abdomen (liver and spleen), and neurological systems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal Hematology laboratory tests</measure>
    <time_frame>Approximately 22 weeks</time_frame>
    <description>Hematology values will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal clinical chemistry laboratory tests</measure>
    <time_frame>Approximately 22 weeks</time_frame>
    <description>Clinical chemistry values will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal routine urinalysis laboratory tests</measure>
    <time_frame>Approximately 22 weeks</time_frame>
    <description>Routine urinalysis parameters will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1) as a measure of safety and tolerability</measure>
    <time_frame>At Day 1 (pre-dose) in both treatment periods and Follow-up (at approximately Week 22)</time_frame>
    <description>It will be measured with subjects in a sitting position using a calibrated spirometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC) as a measure of safety and tolerability</measure>
    <time_frame>At Day 1 (pre-dose) in both treatment periods and Follow-up (at approximately Week 22)</time_frame>
    <description>It will be measured with subjects in a sitting position using a calibrated spirometer</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm AB - FF followed by FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AC - FF followed by BUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm AD - FF followed by ELLIPTA Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BA - FP followed by FF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BC - FP followed by BUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm BE - FP followed by DISKUS Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm CA - BUD followed by FF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm CB - BUD followed by FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm CE - BUD followed by DISKUS Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm DA - ELLIPTA Placebo followed by FF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm EB - DISKUS Placebo followed by FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm DC - ELLIPTA Placebo followed by BUD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone furoate (FF) Dry Powder Inhaler</intervention_name>
    <description>Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods</description>
    <arm_group_label>Arm DA - ELLIPTA Placebo followed by FF</arm_group_label>
    <arm_group_label>Arm AD - FF followed by ELLIPTA Placebo</arm_group_label>
    <arm_group_label>Arm CA - BUD followed by FF</arm_group_label>
    <arm_group_label>Arm AB - FF followed by FP</arm_group_label>
    <arm_group_label>Arm BA - FP followed by FF</arm_group_label>
    <arm_group_label>Arm AC - FF followed by BUD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate (FP) Dry Powder Inhaler</intervention_name>
    <description>Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods</description>
    <arm_group_label>Arm EB - DISKUS Placebo followed by FP</arm_group_label>
    <arm_group_label>Arm BC - FP followed by BUD</arm_group_label>
    <arm_group_label>Arm AB - FF followed by FP</arm_group_label>
    <arm_group_label>Arm BA - FP followed by FF</arm_group_label>
    <arm_group_label>Arm CB - BUD followed by FP</arm_group_label>
    <arm_group_label>Arm BE - FP followed by DISKUS Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide (BUD) Turbuhaler</intervention_name>
    <description>Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.</description>
    <arm_group_label>Arm BC - FP followed by BUD</arm_group_label>
    <arm_group_label>Arm CA - BUD followed by FF</arm_group_label>
    <arm_group_label>Arm DC - ELLIPTA Placebo followed by BUD</arm_group_label>
    <arm_group_label>Arm CE - BUD followed by DISKUS Placebo</arm_group_label>
    <arm_group_label>Arm AC - FF followed by BUD</arm_group_label>
    <arm_group_label>Arm CB - BUD followed by FP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (ELLIPTA or DISKUS)</intervention_name>
    <description>Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.</description>
    <arm_group_label>Arm DA - ELLIPTA Placebo followed by FF</arm_group_label>
    <arm_group_label>Arm EB - DISKUS Placebo followed by FP</arm_group_label>
    <arm_group_label>Arm AD - FF followed by ELLIPTA Placebo</arm_group_label>
    <arm_group_label>Arm DC - ELLIPTA Placebo followed by BUD</arm_group_label>
    <arm_group_label>Arm CE - BUD followed by DISKUS Placebo</arm_group_label>
    <arm_group_label>Arm BE - FP followed by DISKUS Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects must be 18 to 65 years of age inclusive, at the time of signing the informed
             Consent.

          -  Documented history of bronchial asthma, first diagnosed at least 6 months prior to the
             screening visit and being treated only with intermittent short-acting beta2-agonist
             therapy by inhalation

          -  Pre-bronchodilator FEV1 &gt;=65% of predicted at screening; the pre-dose baseline FEV1
             should be +/-15% of the screening baseline value and &gt;=65% predicted for the subject
             to continue

          -  Documented sensitivity to AMP with a provocative concentration of AMP resulting in a
             fall of &gt;=20% FEV1 with a PC20 AMP &lt;=80 mg/mL at the screening visit

          -  Demonstrated stable bronchoconstriction in response to inhaled AMP at the run-in
             visit. The run-in PC20 to be within 1.25 doubling concentration of the screening PC20.

          -  Current therapy could include short-acting Beta2-agonists (SABA) prescribed SABA for
             at least 12 weeks prior to screening, if needed; no ICS, Long-acting beta2-agonist
             (LABA), long-acting muscarinic antagonist (LAMA), leukotriene receptor antagonist
             (LTRA) therapy for three months prior to the start of the study; and no biological
             therapies for at least 6 months prior to start of the study.

          -  Bodyweight &gt;=50 Kilogram (kg) and BMI within the range 18.0-35.0 kg/meter (m)^2
             (inclusive)

          -  Male and female.

        Females:

        A female subject is eligible to participate if she is not pregnant (as confirmed by a
        negative urine human chorionic gonadotrophin [HCG] test), not lactating, and at least one
        of the following conditions applies prior to randomization:

          -  Non-reproductive potential defined as pre-menopausal females with one of the
             following: Documented tubal ligation; Documented hysteroscopic tubal occlusion
             procedure with follow-up confirmation of bilateral tubal occlusion; Hysterectomy;
             Documented Bilateral Oophorectomy; Postmenopausal defined as 12 months of spontaneous
             amenorrhea, in questionable cases a blood sample with simultaneous follicle
             stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on
             hormone replacement therapy (HRT) and whose menopausal status is in doubt will be
             required to use one of the highly effective contraception methods if they wish to
             continue their HRT during the study. Otherwise, they must discontinue HRT to allow
             confirmation of post-menopausal status prior to study enrolment.

          -  Reproductive potential and agrees to follow one of the highly effective methods for
             avoiding pregnancy in females of reproductive potential from 30 days prior to the
             first dose of study drug and until at least five terminal half-lives after the last
             dose of study drug. The investigator is responsible for ensuring that subjects
             understand how to properly use methods of contraception.

               -  Aspartate aminotransferase and Alanine transaminase &lt;2x upper limit of normal
                  (ULN); alkaline phosphatase and bilirubin â‰¤1.5 x ULN (isolated bilirubin &gt;1.5xULN
                  is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)

               -  Having provided written informed consent, which includes compliance with the
                  requirements and restrictions listed in the consent form.

        Exclusion Criteria:

          -  A history of life-threatening asthma, defined as an asthma episode that required
             intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic
             seizures within the last 5 years.

          -  Other significant pulmonary diseases to include (but not limited to) severe pneumonia
             within 6 months of the screening visit, pneumothorax, atelectasis, pulmonary fibrotic
             disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic
             obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other
             than asthma.

          -  Culture-documented or suspected bacterial or viral infection of the upper or lower
             respiratory tract, sinus or middle ear within 4 weeks of screening that: In the
             opinion of the investigator, is expected to affect the subject's asthma status or the
             subject's ability to participate in the study.

          -  A subject will not be eligible if he/she has clinical visual evidence of oral
             candidiasis at screening.

          -  Any asthma exacerbation requiring oral corticosteroids within 12 weeks of screening or
             that resulted in overnight hospitalization requiring additional treatment for asthma
             within 6 months prior to randomization.

          -  Use of prohibited medications including, anti-depressant drugs, and anti-asthma drugs
             (other than short acting inhaled beta-agonists supplied as rescue medication, oral
             contraceptives, non-steroidal anti-inflammatory drugs, stable doses of antihistamines,
             and paracetamol) for 1 week prior to screening and throughout the course of the study.
             Anti-histamines should be withheld 4 days prior to AMP challenge; subjects must also
             be able to abstain from short acting inhaled beta-agonists, for 8 hours prior to
             spirometry.

          -  Subjects undergoing de-sensitization therapy

          -  Current smokers or a smoking history of &gt;=10 pack years. A subject must not have used
             any inhaled tobacco products in the 12 month period preceding the screening visit.

          -  History of regular alcohol consumption exceeding 21 units per week for men and 14
             units per week for females (1 unit =5 ounces [150 mL] of wine or 12 ounces [360 mL] of
             beer or 1.5 ounces [45 mL] of spirits) within 6 months of screening.

          -  All subjects who are currently or in the last month have worked night-shifts are
             excluded from the study

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day or received an investigational product within 30 days of study start, or 5
             half-lives of study drug if that is longer.

          -  A subject has any clinically significant, uncontrolled condition or disease state
             that, in the opinion of the investigator, would put the safety of the subject at risk
             through study participation or would confound the interpretation of the study results
             if the condition/disease exacerbated during the study. (e.g. stroke or myocardial
             infarction within 3 months, uncontrolled hypertension, congestive heart failure,
             uncontrolled diabetes mellitus.)

          -  Evidence of cancer or history of cancer in the past 5 years other than adequately
             treated basal or squamous cell carcinoma of the skin or adequately treated in situ
             carcinoma of the cervix.

          -  Pregnant females as determined by positive urine HCG test at screening or by positive
             urine HCG test prior to dosing and lactating females.

          -  Subjects with active or chronic infections including hepatitis B or C, human
             immunodeficiency virus. A positive serology at screening.

          -  Allergies:

        History of severe milk protein allergy Drug Allergy defined as any adverse reaction
        including immediate or delayed hypersensitivity to intranasal, inhaled, or systemic
        corticosteroid therapy. Known or suspected sensitivity to the constituents of FF, FP or BUD
        (i.e., lactose or magnesium stearate) Historical Allergy defined as history of drug or
        other allergy that, in the opinion of the investigator or GSK Medical Monitor,
        contraindicates their participation.

          -  Significant abnormality in the 12-lead electrocardiogram (ECG) performed at screening.
             The mean of the three individual ECGs will be taken. Mean QT interval corrected for
             heart rate (QTc) &gt;450 millisecond (msec) for males or QTc&gt;470 msec for female subjects
             and &gt;480 in subjects with bundle branch block. The QTc is the QT interval corrected
             for heart rate according to Fridericia's formula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-response</keyword>
  <keyword>AMP challenge</keyword>
  <keyword>cortisol suppression</keyword>
  <keyword>dose escalation</keyword>
  <keyword>therapeutic index</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

